U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H67NO13
Molecular Weight 733.9282
Optical Activity UNSPECIFIED
Defined Stereocenters 18 / 18
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERYTHROMYCIN

SMILES

CC[C@]1([H])[C@](C)([C@@]([H])([C@@]([H])(C)C(=O)[C@]([H])(C)C[C@](C)([C@@]([H])([C@@]([H])(C)[C@@]([H])([C@@]([H])(C)C(=O)O1)O[C@@]2([H])C[C@](C)([C@]([H])([C@]([H])(C)O2)O)OC)O[C@@]3([H])[C@@]([H])([C@]([H])(C[C@@]([H])(C)O3)N(C)C)O)O)O)O

InChI

InChIKey=ULGZDMOVFRHVEP-RWJQBGPGSA-N
InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1

HIDE SMILES / InChI
Molecular Formula C37H67NO13
Molecular Weight 733.9282
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 18 / 18
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/7023159 | http://www.polfa-tarchomin.com.pl/wp-content/uploads/2013/07/Ulotka_Davercin-tabletki-powlekane-250mg.pdf | https://www.doz.pl/leki/p2615-Davercin_tabletki

Erythromycin cyclocarbonate (Davercin) is a first generation semi-synthetic erythromycin. It is active against Gram-positive and some Gram-negative microorganisms. Davercin shows comparable or better in vitro potency, low host toxicity and improved pharmacokinetics compared with erythromycin. It is approved for the treatment of acne, atypical pneumonia (caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila), whooping cough (treatment and prevention), urethritis (caused by Ureaplasma urealyticum and Chlamydia trachomatis), gastrointestinal infection caused by Campylobacter spp., short-term infections of the skin and soft tissues (e.g. acne, staphylococcal dermatitis). In streptococcal infections, diphtheria, gonorrhea, early syphilis in patients who are allergic to penicillin, and in the prevention of bacterial endocarditis before the planned dental procedures. Adverse effects are: nausea, vomiting, abdominal pain, diarrhea, skin allergic reactions.

CNS Activity

CNS Penetrant
2415
Curator's Comment:: Information about erythromycin ethylsuccinate is unavailable.

Originator

Eli Lilly
225
Curator's Comment:: H. Bojarska-Dahlig and W. Slawinski, Rocz. Chern. 46, 2211 (1972)

Approval Year

1952
97
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
994
Skin and skin structure infections
Respiratory tract infections
Listeriosis
Diphtheria
Erythrasma
 14 nM [Kd]
Inhibitor
7701
Acne
Pneumonia
Bacterial endocarditis
Staphylococcal dermatitis
Binding Agent
994
Respiratory tract infections
Skin and skin structure infections
Diphtheria
Listeriosis
Erythrasma
 14 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Bacterial 70S ribosome
Approved
7997
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

79660800000
Curative
Bacterial 70S ribosome
Approved
7997
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

79660800000
Curative
Bacterial 70S ribosome
Approved
7997
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

79660800000
Curative
Bacterial 70S ribosome
Approved
7997
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

79660800000
Curative
Bacterial 70S ribosome
Approved
7997
Erythromycin

Approved Use

Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection.

Launch Date

79660800000
Curative
Bacterial 70S ribosome
Approved
7997
Davercin

Approved Use

For the topical treatment of acne vulgaris
Curative
Bacterial 70S ribosome
Approved
7997
Davercin

Approved Use

For the topical treatment of pneumonia
Curative
Bacterial 70S ribosome
Approved
7997
Davercin

Approved Use

Indicated for the treatment of bacterial endocarditis
Curative
Bacterial 70S ribosome
Approved
7997
Davercin
Curative
Bacterial 70S ribosome
Approved
7997
E.E.S.

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

-149990400000
Curative
Bacterial 70S ribosome
Approved
7997
E.E.S.

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

-149990400000
Curative
Bacterial 70S ribosome
Approved
7997
E.E.S

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

-149990400000
Curative
Bacterial 70S ribosome
Approved
7997
E.E.S.

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

-150076800000
Curative
Bacterial 70S ribosome
Approved
7997
E.E.S.

Approved Use

E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

Launch Date

-150076800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.18 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.44 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.62 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
250 mg 4 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.99 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
250 mg 4 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1161.5 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1386.1 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.1 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.1 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6628511/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3544.7 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4096.7 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.48 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.31 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERYTHROMYCIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
5 g 1 times / day single, oral
Studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: single
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
healthy, 12 years
Health Status: healthy
Age Group: 12 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
Other AEs: Pancreatitis...
Other AEs:
Pancreatitis
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
5.3 g 1 times / day single, oral
Studied dose
Dose: 5.3 g, 1 times / day
Route: oral
Route: single
Dose: 5.3 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
healthy, 15 years
Health Status: healthy
Age Group: 15 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
Other AEs: Pancreatitis...
Other AEs:
Pancreatitis
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
Health Status: unhealthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (2.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
500 mg 3 times / day multiple, oral
Recommended
Dose: 500 mg, 3 times / day
Route: oral
Route: multiple
Dose: 500 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
Health Status: unhealthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Disc. AE: Nausea, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Nausea (14.6%)
Abdominal pain (4.9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
unhealthy, mean age 44 years
Health Status: unhealthy
Age Group: mean age 44 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
Disc. AE: Epigastralgia, Nausea...
AEs leading to
discontinuation/dose reduction:
Epigastralgia (grade 2-3, 2.5%)
Nausea (grade 3, 3.3%)
Vomiting (grade 2, 0.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
100 mg single, intravenous
Dose: 100 mg
Route: intravenous
Route: single
Dose: 100 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
Other AEs: Akathisia, Diarrhea...
Other AEs:
Akathisia (below serious, 1 patient)
Diarrhea (below serious, 1 patient)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
AEs

AEs

AESignificanceDosePopulation
Pancreatitis
5 g 1 times / day single, oral
Studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: single
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
healthy, 12 years
Health Status: healthy
Age Group: 12 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1408521/
Pancreatitis
5.3 g 1 times / day single, oral
Studied dose
Dose: 5.3 g, 1 times / day
Route: oral
Route: single
Dose: 5.3 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
healthy, 15 years
Health Status: healthy
Age Group: 15 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16215473/
Vomiting 2.8%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
Health Status: unhealthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Nausea 14.6%
Disc. AE
500 mg 3 times / day multiple, oral
Recommended
Dose: 500 mg, 3 times / day
Route: oral
Route: multiple
Dose: 500 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
Health Status: unhealthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Abdominal pain 4.9%
Disc. AE
500 mg 3 times / day multiple, oral
Recommended
Dose: 500 mg, 3 times / day
Route: oral
Route: multiple
Dose: 500 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
unhealthy, mean age 30 years
Health Status: unhealthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/241119/
Vomiting grade 2, 0.8%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
unhealthy, mean age 44 years
Health Status: unhealthy
Age Group: mean age 44 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
Epigastralgia grade 2-3, 2.5%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
unhealthy, mean age 44 years
Health Status: unhealthy
Age Group: mean age 44 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
Nausea grade 3, 3.3%
Disc. AE
500 mg 2 times / day multiple, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
unhealthy, mean age 44 years
Health Status: unhealthy
Age Group: mean age 44 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/2140547/
Akathisia below serious, 1 patient
100 mg single, intravenous
Dose: 100 mg
Route: intravenous
Route: single
Dose: 100 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
Diarrhea below serious, 1 patient
100 mg single, intravenous
Dose: 100 mg
Route: intravenous
Route: single
Dose: 100 mg
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT02005029
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1172
inhibitor
1360

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1268

P-gp
1089

OATP1B1
698

OATP1B3
613
CYP3A
154

OAT2
108
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1406
 likely
CYP3A4
1462
 moderate [IC50 9.9 uM]
yes (co-administration study)
Comment: Erythromycin increased mean Cmax value of simvastatin 3.4 fold and AUC0-24 value 6.2 fold; coadministered erythromycin has been reported to increase AUCs of simvastatin, triazolam, and midazolam 6.2-, 3.6-, and 3.8-fold, respectively; A significant increase in colchicine plasma concentration is anticipated when co-administered with moderate CYP3A4 inhibitors such as erythromycin;
Page: 10
OATP1B1
713
 yes [IC50 217 uM]
P-gp
1255
 yes [IC50 22.7 uM]
OATP1B3
622
 yes [IC50 34 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OAT2
108
 yes
CYP3A
154
 yes
likely (co-administration study)
Comment: Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug
Page: 9
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1392
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY34447
1PlusChem LLC
1P0039QP
A2B Chem
AB51793
AK Scientific
2109AH
AK Scientific
E909
AK Scientific
H891
AK Scientific
J10493
AK Scientific
W0032
APExBIO
B1939
AbovChem LLC
HY-B0220
Alfa Chemistry
16667-03-1
Alfa Chemistry
ACM114078
Alfa Chemistry
ACM3847298
Alfa Chemistry
ACM4501002
Alfa Chemistry
ACM54579178
Ambeed
A199997
Apollo Scientific
BIE0122
AstaTech
40182
BLDpharm
BD17733
BOC Sciences
114-07-8
BOC Sciences
16667-03-1
BOC Sciences
23067-13-2
BOC Sciences
3847-29-8
BOC Sciences
4501-00-2
BOC Sciences
59319-72-1
BOC Sciences
643-22-1
BOC Sciences
7704-67-8
BioSynth
E-3250
BioSynth
Q-201067
BioSynth
Q-201068
BioSynth
W-104851
Bosche Scientific
E2056
Bosche Scientific
E6561
Bosche Scientific
E6569
Cayman Chemical
16486
Cayman Chemical
17189
Chem Scene
CS-2168
Chem-Impex International
126
ChemShuttle
159902
Compound Cloud
12559
Compound Cloud
12560
Compound Cloud
16051953
Compound Cloud
20055320
Compound Cloud
71469
Compound Cloud
83938
Enamine
EN300-1485622
Fluorochem
94643
Hangzhou APIChem Technology
AC-12744
Hangzhou APIChem Technology
AC-12901
Hangzhou Yuhao Chemical Technology
HL1432
Hangzhou Yuhao Chemical Technology
JZ4084
IBScreen
BB_NC-01332
IBScreen
STOCK1N-53062
Indofine
BIO-177
KeyOrganics
AS-13879
Lab Seeker
SC-13736
MedChem Express
HY-B0220
MolPort
MolPort-002-507-378
MolPort
MolPort-003-939-312
MolPort
MolPort-006-069-174
MolPort
MolPort-006-115-742
MolPort
MolPort-009-758-388
MolPort
MolPort-023-220-297
Molcore
MC34447
Molnova
M10494
Oakwood
94643
Pharmeks
PHBB_NC-02691
Ryan Scientific
Paromomycin_Sulfate
Sigma Aldrich
1242000
Sigma Aldrich
1242000|USP
Sigma Aldrich
45674
Sigma Aldrich
45674|SIAL
Sigma Aldrich
45703
Sigma Aldrich
45703|SIGMA
Sigma Aldrich
46256
Sigma Aldrich
46256|SIAL
Sigma Aldrich
856193
Sigma Aldrich
856193|ALDRICH
Sigma Aldrich
BP794
Sigma Aldrich
E0774
Sigma Aldrich
E0774|SIAL
Sigma Aldrich
E1300000
Sigma Aldrich
E1300000|SIAL
Sigma Aldrich
E1305000
Sigma Aldrich
E1305000|SIAL
Sigma Aldrich
E4514
Sigma Aldrich
E4514|SIGMA
Sigma Aldrich
E5389
Sigma Aldrich
E5389|SIGMA
Sigma Aldrich
E6376
Sigma Aldrich
E6376|SIAL
Sigma Aldrich
E7904
Sigma Aldrich
E7904|SIGMA
Sigma Aldrich
PHR1039
Sigma Aldrich
PHR1039|SIAL
StruChem
SC-13736
TargetMol
T1032
Tetrahedron
TS84730
Toronto Research Chemicals
A189653
ZINC
ZINC000085534336
http://zinc15.docking.org/substances/ZINC000085534336
eMolecules
193074747
eMolecules
260190374
eMolecules
30512590
eMolecules
313125893
eMolecules
35780477
eMolecules
37093077
eMolecules
43297831
eMolecules
44815835
eMolecules
45919336
eMolecules
48351022
eMolecules
6842882
mcule
MCULE-2830244120
mcule
MCULE-4566208867
PubMed

PubMed

TitleDatePubMed
Drug-induced gallbladder disease. Incidence, aetiology and management.
1992 Jan-Feb
The in-vitro activity of two new quinolones: rufloxacin and MF 961.
1992 Jun
[Bacteriostatic activity and killing curves of eight antibiotics against seven strains of penicillin G-resistant pneumococci].
1992 May
[In vitro activity of sparfloxacin against mycoplasmas].
1992 May
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
Massive venlafaxine overdose resulted in a false positive Abbott AxSYM urine immunoassay for phencyclidine.
2003
Mixed chimerism of erythro- and megakaryopoiesis following allogeneic bone marrow transplantation.
2003
Effects of amphotericin B and caspofungin on histamine expression.
2003 Aug
Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.
2003 Dec 1
Effect of erythromycin on contractile response of uterine smooth muscle strips in non-pregnant rats.
2003 Jan-Feb
Ratio of erythro and threo forms of beta-O-4 structures in tension wood lignin.
2003 Nov
[Hantavirus-induced acute renal failure. A case report].
2003 Oct
A novel three-component reaction catalyzed by dirhodium(II) acetate: decomposition of phenyldiazoacetate with arylamine and imine for highly diastereoselective synthesis of 1,2-diamines.
2003 Oct 16
Isolation and antimicrobial susceptibility of Aeromonas salmonicida in rainbow trout (Oncorhynchus mykiss) in turkey hatchery farms.
2003 Sep
The relationship of physico-chemical properties and structure to the differential antiplasmodial activity of the cinchona alkaloids.
2003 Sep 1
erythro-1-Naphthyl-1-(2-piperidyl)methanol: synthesis, resolution, NMR relative configuration, and VCD absolute configuration.
2003 Sep 19
Straightforward synthesis of sphinganines via a serine-derived Weinreb amide.
2004 Apr 30
Bitterness evaluation of medicines for pediatric use by a taste sensor.
2004 Aug
Delayed Gastric Emptying in Functional Dyspepsia.
2004 Aug
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
2004 Dec
Local mechanisms underlying the regulatory effect of Kropanol on hemopoiesis during paradoxical sleep deprivation.
2004 Feb
Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis.
2004 Feb
[3 + 2] Cycloreversion of bicyclo[m.3.0]alkan-3-on-2-yl-1-oxonium ylides to alkenyloxyketenes. Stereospecific aspect.
2004 Feb 20
Cytochrome P450/NADPH-dependent formation of trans epoxides from trans-arachidonic acids.
2004 Feb 23
Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels.
2004 Jul
Highly diastereoselective reductive coupling of 2-bromo-2,3,3,3-tetrafluoropropanamide with aldehydes promoted by triphenylphosphine-titanium(IV) isopropoxide. An efficient route to the synthesis of erythro-alpha-fluoro-alpha-(trifluoromethyl)-beta-hydroxy amides.
2004 Jul 23
[Usefulness of oral exfoliative cytology for the diagnosis of oral squamous dysplasia and carcinoma].
2004 Mar
Effect of particle size on mixing degree in dispensation.
2004 Mar
Effect of mixing method on the mixing degree during the preparation of triturations.
2004 Mar
Conformational study of a guaiacyl beta-O-4 lignin model compound by NMR. Examination of intramolecular hydrogen bonding interactions and conformational flexibility in solution.
2004 Mar
Mechanism of beta-silyl diacyl peroxide decomposition: a mild and stereoselective synthesis of beta-silyl esters.
2004 May 28
Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro.
2004 Nov
Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
2004 Nov
Enantiomeric separation of racemic neolignans on chiralcel OD and determination of their absolute configuration with online circular dichroism.
2004 Oct
Effects of colchicine on the maximum biliary excretion of cholephilic compounds in rats.
2004 Sep
Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia.
2005
In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis.
2005 Apr
Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns?
2005 Apr
Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK).
2005 Aug
On the CH...Cu agostic interaction: chiral copper(II) compounds with ephedrine and pseudoephedrine derivatives.
2005 Aug 14
Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne.
2005 Jan
High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line.
2005 Jan
On-line identification of sugarcane (Saccharum officinarum L.) methoxyflavones by liquid chromatography-UV detection using post-column derivatization and liquid chromatography-mass spectrometry.
2005 Jul 29
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Desensitization of the human motilin receptor by motilides.
2005 Jun
Molecular recognition of sialic acid end groups by phenylboronates.
2005 Jun 20
[Biological effects of a natural alkyl-diacylglyceride preparation in rats with experimental cardioangiopathy].
2005 Mar-Apr
Cytotoxicity of neolignans identified in Saururus chinensis towards human cancer cell lines.
2005 May
Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]).
2005 May
The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine.
2005 May
Patents

Patents

03963579
26
06794372
28
EP0119431 A1
26
JP2000229993A
26
JP2000516450A
29
JP2001521945A
45
JP2002121197A
26
JP2002241392A
26
JP2002511777A
382
JP2002520071A
27
JP2002521468A
35
JP2004323414A
26
JP2006137765A
26
JP2006514917A
59
JP2007505906A
44
JP2009137975A
26
JP2009513190A
32
JP2011508747A
59
JP2011526302A
65
JPH06189748A
26
JPH06199887A
26
JPH07247299A
26
JPH07278177A
26
JPH1072457A
26
JPH11322777A
26
JPS05785319A
26
JPS56125382A
26
JPS56147798A
26
JPS58159500A
26
JPS61291516A
32
JPS62115299A
26
JPS62294623A
35
JPS6287599A
26
JPS6423A
26
JPS6466122A
26
US20140128583
26
US2653899
26
US4219641
26
US5118799
26

Sample Use Guides

In Vivo Use Guide
The usual dosage of erythromycin tablets is one 250 mg tablet four times daily in equally spaced doses or one 500 mg tablet every 12 hours. Dosage may be increased up to 4 g per day according to the severity of the infection. However, twice-a-day dosing is not recommended when doses larger than 1 g daily are administered.
Route of Administration: Oral
In Vitro Use Guide
The MIC values for erythromycin were: 0.25-1 ug/ml (Staphylococcus aureus ATCC 29213), 1-4 ug/ml (Enterococcus faecalis ATCC 29212), 0.03-0.12 ug/ml (Streptococcus pneumoniae ATCC 49619).
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:58:28 UTC 2021
Edited
by admin
on Fri Jun 25 20:58:28 UTC 2021
Record UNII
63937KV33D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ERYTHROMYCIN
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
ERYTHROMYCIN [MART.]
Common Name English
TORLAMICINA
Common Name English
ROBIMYCIN
Brand Name English
A/T/S
Brand Name English
ERYTHROMYCINUM [WHO-IP LATIN]
Common Name English
ERYTHROMYCIN [ORANGE BOOK]
Common Name English
ERYGEL
Brand Name English
E-SOLVE 2
Brand Name English
ERYTHROMYCIN [HSDB]
Common Name English
ERYCETTE
Brand Name English
ERYTHROMYCIN COMPONENT OF BENZAMYCIN
Common Name English
E-GLADES
Brand Name English
NSC-55929
Code English
ERYTHRA-DERM
Brand Name English
ERYTHROMYCIN-A
Common Name English
E-BASE
Brand Name English
ERYTHROMYCIN A
Common Name English
ERYTHROMYCIN [EP MONOGRAPH]
Common Name English
PCE (ERYTHROMYCIN)
Brand Name English
ERYTHRO-STATIN
Brand Name English
ERY-TAB
Brand Name English
PANTOMICINA
Common Name English
ERYTHROMYCIN [WHO-IP]
Common Name English
R-P MYCIN
Brand Name English
ILOTYCIN
Brand Name English
ERYTHROMYCIN [GREEN BOOK]
Common Name English
ERYTHROMYCIN [INN]
Common Name English
T-STAT
Brand Name English
ERYTHROMYCIN [WHO-DD]
Common Name English
STATICIN
Brand Name English
ERYTHROMYCIN ESTOLATE IMPURITY, FREE ERYTHROMYCIN- [USP]
Common Name English
J01FA01
Code English
ERYDERM
Brand Name English
SANSAC
Brand Name English
EMGEL
Brand Name English
AKNE-MYCIN
Brand Name English
BENZAMYCIN COMPONENT ERYTHROMYCIN
Common Name English
ERYTHROMYCIN [VANDF]
Common Name English
ERYMAX
Brand Name English
ERYTHROMYCIN [MI]
Common Name English
ERYTHROMYCIN ESTOLATE SPECIFIED IMPURITY, FREE ERYTHROMYCIN [EP]
Common Name English
ERYTHROMYCIN [USP MONOGRAPH]
Common Name English
E-MYCIN
Brand Name English
ERYC
Brand Name English
ERYTHROMYCIN [USP-RS]
Common Name English
C-SOLVE-2
Brand Name English
Classification Tree Code System Code
NDF-RT N0000007529
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
WHO-ATC S01AA17
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
WHO-ATC D10AF52
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
LIVERTOX 367
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
WHO-ATC D10AF02
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
NDF-RT N0000175877
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
WHO-VATC QJ51RF02
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.2
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
CFR 21 CFR 520.823
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
WHO-VATC QD10AF02
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
WHO-VATC QS01AA17
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
NDF-RT N0000007529
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
NDF-RT N0000009982
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
NCI_THESAURUS C261
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
WHO-VATC QJ01FA01
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
WHO-VATC QJ51FA01
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
NDF-RT N0000175935
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
WHO-ATC J01FA01
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
CFR 21 CFR 522.820
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
CFR 21 CFR 526.820
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
CFR 21 CFR 556.230
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
CFR 21 CFR 558.248
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
NDF-RT N0000007529
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL2110577
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
ChEMBL
CHEMBL532
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
PUBCHEM
12560
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
LACTMED
Erythromycin
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
IUPHAR
1456
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
EVMPD
SUB06605MIG
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
HSDB
3074
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
FDA UNII
63937KV33D
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
DRUG CENTRAL
1048
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
INN
39
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
DRUG BANK
DB00199
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
RXCUI
4053
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY RxNorm
WHO INTERNATIONAL PHARMACOPEIA
ERYTHROMYCIN
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY Description: White or slightly yellow crystals or powder; odourless or almost odourless.Solubility: Soluble in 1000 parts of water but less soluble in hot water; freely soluble in ethanol (~750 g/l) TS and ether R.Category: Antibacterial drug.Storage: Erythromycin should be kept in a tightly closed container, protected from light.Additional information: Erythromycin is slightly hygroscopic.Definition: Erythromycin is a mixture of substances produced by the growth of certain strains of Streptomyces erythreus. The main component of the mixture is erythromycin A with lesser amounts of erythromycins B and C.
EPA CompTox
114-07-8
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
WIKIPEDIA
ERYTHROMYCIN
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
MERCK INDEX
M5009
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C476
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
CAS
114-07-8
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
USP_CATALOG
1242000
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY USP-RS
MESH
D004917
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
ECHA (EC/EINECS)
204-040-1
Created by admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> INHIBITOR
Structure of ERYTHROMYCIN HYDRIODIDE MONOHYDRATE
SALT/SOLVATE -> PARENT
Structure of ERYTHROMYCIN OXALATE DIHYDRATE
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of ERYTHROMYCIN C-13
LABELED -> NON-LABELED
CYTOCHROME P450 3A12 (CANINE)
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 3A5
METABOLIC ENZYME -> SUBSTRATE
Structure of ERYTHROMYCIN ESTOLATE
SUBSTANCE->BASIS OF STRENGTH
ALDEHYDE OXIDASE
METABOLIC ENZYME -> INHIBITOR
IC50
Structure of ERYTHROMYCIN N-METHYL C-14
LABELED -> NON-LABELED
CYTOCHROME P450 1A2 (CANINE)
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
Structure of ERYTHROMYCIN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC POPULATION: ADULTS

MIC BIOLOGICAL SUSCEPTIBILITY: S. PNEUMONIAE, S. PYOGENES

MIC BIOLOGICAL SUSCEPTIBILITY: S. PNEUMONIAE, S. PYOGENES

Tmax PHARMACOKINETIC COMBINATION FORM: ERYTHROMYCIN ETHYLSUCCINATE

FOOD EFFECT: DELAYED Tmax

Biological Half-life PHARMACOKINETIC POPULATION: END-STAGE RENAL DISEASE

Volume of Distribution PHARMACOKINETIC
MIC BIOLOGICAL SUSCEPTIBILITY: S. AUREUS

MIC BIOLOGICAL SUSCEPTIBILITY: S. AUREUS

Tmax PHARMACOKINETIC FOOD EFFECT: DELAYED Tmax

COMBINATION FORM: ERYTHROMYCIN STEARATE

Tmax PHARMACOKINETIC FOOD EFFECT: BASE

COMBINATION FORM: ERYTHROMYCIN BASE

MIC BIOLOGICAL SUSCEPTIBILITY: S. PNEUMONIAE, S. PYOGENES

Biological Half-life PHARMACOKINETIC POPULATION: NEONATES (LESS THAN OR EQUAL TO 15 DAYS OF AGE)

MIC BIOLOGICAL SUSCEPTIBILITY: S. AUREUS

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966